Price
44.2
+2.93%Market Cap
₹60.17 Cr
Traded: ₹0.01 Cr (0.01%) 0.0x
Free Float: ₹13.92 Cr (0.06% of FF traded)
Volume · 60D trend
2 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Return | -- | -- | -- | +4.0% | -- | -- |
| ROE | -- | +25.0% | +16.0% | -- | -- | Decelerating |
| Sales | -- | -- | +9.0% | -- | +4.0% | Decelerating |
| Profit | -- | -- | -4.0% | -- | +0.0% | Accelerating |
Quarterly Results
Sep 2024
Mar 2024
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Sep 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| Sales | 12 | 11 | 25 | 11 | 23 | 25 | 22 |
| Expenses | 10 | 9 | 20 | 9 | 19 | 20 | 18 |
| Operating Profit | 2 | 2 | 5 | 2 | 4 | 4 | 4 |
| OPM % | 17.7% | 16.9% | 18.4% | 18.3% | 16.4% | 17.9% | 19.7% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 1 | 1 | 3 | 1 | 2 | 3 | 3 |
| Tax % | 25.2% | 24.5% | 25.9% | 26.9% | 26.1% | 26.0% | 25.3% |
| Net Profit | 1 | 1 | 2 | 1 | 2 | 2 | 2 |
| Exceptional Items | -- | 0 | 0 | -- | 0 | 0 | -0 |
| EPS (Rs) | 0.7 | 0.8 | 1.5 | 0.7 | 1.3 | 2.4 | 2.5 |
| Sales Growth (YoY) | -- | -1.8% | 0.0% | -- | 6.1% | -- | -- |
| Sales Growth (QoQ) | -- | -7.3% | 6.0% | -- | -5.7% | 12.5% | -- |
| OP Growth (YoY) | 0.0% | -52.0% | 2.7% | -- | -11.8% | -- | -- |
| OP Growth (QoQ) | 14.8% | -- | 116.2% | -44.9% | -- | -- | -- |
| Profit Growth (YoY) | -- | -- | -- | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 21.8% | -39.3% | -- | -47.4% | -- | -- |
| EPS Growth (QoQ) | -- | 9.5% | 11.3% | -- | -45.5% | -3.6% | -- |
| OP Margin | -- | 16.4% | 18.4% | -- | 16.4% | 17.9% | 19.7% |
| Net Margin | -- | 9.6% | 8.2% | -- | 7.8% | 9.7% | 11.3% |
| Material Cost % | -- | 29.0% | 33.0% | -- | 34.7% | 39.2% | 41.4% |
| Employee Cost % | -- | 17.1% | 14.9% | -- | 11.0% | 12.4% | 7.6% |
| P/S | 1.27 | 1.28 | -- | -- | -- | -- | -- |
| P/E | 14.26 | 14.35 | -- | -- | -- | -- | -- |
| P/B | 1.42 | 1.43 | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper Advertisement- 06th Annual General Meeting through Video Conferencing/Other Audio-Visual Means("VC/OAVM") facility
Alteration of the Memorandum of Association by insertion of new object clauses and alteration of the Articles of Association of the company, subject to the approval of the Members of the Company.
Increase in the Authorised Share Capital of the Company from Rs. 14,00,00,000 (Rupees Fourteen Crores) to Rs. 25,00,00,000 (Rupees Twenty Five Crores) subject to approval of the Members ....
Unaudited Financial Results for the Quarter Ended June 30, 2026
The Board has approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2026, formulated the Employee Stock Option Plan 2026, and fixed the date of the 6th ....
The Company has initiated the testing phase of its mobile application "Shanmuga 360".
Certificate pursuant to Regulation 74(5) SEBI (DP) Regulations, 2018 for the period from 01.04.2026 to 30.06.2026
Execution of Memorandum of Agreement with Central Government Health Scheme(CGHS), Ministry of Health & Family Welfare, Government of India
Closure of Trading window
Audited Financial Results For The Half Year and Year Ended March 31, 2026.
Re-Appointment of Internal Auditors for the Financial Year 2026-27
Approval of Audited Financial Results for the Half-year and year ended 31st March 2026.
Shanmuga Hospital Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2026 ,inter alia, to consider and approve The Audited Financial Results ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Certificate pursuant to Regulation 74(5) SEBI(DP) Regulations, 2018 for the period from 01.01.2026 to 31.03.2026.
Closure of Trading Window
We hereby inform you that Dr Vaishak M.L., Chief Operations Officer, has tendered his resignation to pursue his growth opportunities outside the organization. Accordingly, he shall be relieved ....
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Appointment of Senior Management Personnel.
Intimation regarding Commissioning and Operationalisation of Litho Evo Laser Machine
Certificate pursuant to Regulation 74(5) of SEBI(DP)regulations, 2018 for the period from 01.10.2025 to 31.12.2025
Investor Presentation under Regulation 30 read with Schedule III of SEBI(LODR), 2015
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Statement on Deviation or Variation for proceeds of public issue for the half year ended 30.09.2025
Unaudited Financial Results For the Half Year Ended 30th September 2025 Together with the Limited review report.
Approval of unaudited financial results for the half year ended 30th September 2025, together with the Limited Review Report.
Shanmuga Hospital Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve the Unaudited Financial Results ....
Certificate pursuant to Regulation 74(5) of SEBI (Depositories & Participants) Regulations,2018 for the period 01.07.2025 to 30.09.2025
Analyst / Investor Meet - Outcome
The Company was recognized for its contribution in the field of multispeciality healthcare.
Closure of Shanmuga Clinics with effect from 30.09.2025
Intimation regarding the investor meet on 08.10.2025 at 01:00 PM (IST)
Outcome of Analysts'''''''' / Institutional Investor'''''''' Meet
Closure of Trading window under SEBI(Prohibition of Insider Trading) Regulations,2015
Voting Results and Consolidated Scrutinizer''s report of the 5th Annual General Meeting of the company.
Outcome/Proceeding of 5th Annual General Meeting
Schedule of Investors'''' meet
We wish to inform that the Register of Members remains closed from Saturday, 13th September 2025, to Friday, 19th September 2025(Both days inclusive), and the record date is 12th September ....
Outcome of Analysts'''''''' / Institutional Investor'''''''' Meet
Intimation regarding the investor meet on 05.09.2025 at 01.30 PM.
Newspaper advertisement for the 05th Annual General Meeting of the Company to be held on September 19, 2025.
05th Annual Report of Shanmuga Hospital Limited for the FY 2024-25
Notice of the 05th Annual General Meeting of Shanmuga Hospital Limited is scheduled to be held on Friday, the 19th September 2025 at 03.00 PM through Video Conference or other Audio Visual Means.
Intimation regarding Commissioning and Operationalization of PH Impedance & Manometry System
Outcome of the Board Meeting
Outcome of Analysts'''' / Institutional Investor'''' Meet
Please find enclosed herewith the revised Investor presentation
Investor Presentation under Regulation 30 read with schedule III of SEBI (LODR) Regulations, 2015
Intimation regarding operationalization of Wipro GE-CT Optima 520-32 Slice CT Scanner
Shanmuga Hospital Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 ,inter alia, to consider and approve Shanmuga Hospital Ltd has ....
Intimation regarding the investor meet on 11.08.2025 at 04.00 PM.
Annual Reports
12025